Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:59:12.758Z.
Calculation as of: 2026-10-06T18:59:12.758Z.
Quote observation: 2026-10-06T18:51:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76ce780248c1f493ccbdb0751af92273333f1ee075484263629f1dd5eb2dbf7e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Virax Biolabs Group Limited
Market Cap
$352721.00
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Virax Biolabs Group Limited (VRAX) | $352721.00 | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $484571.00 | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $530421.00 | N/A |
| HCW Biologics Inc. (HCWB)vs › | $568741.00 | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108771.00 | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $96215.00 | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70876.00 | N/A |
| Akanda Corp. (AKAN)vs › | $61819.00 | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
